An observational study in Nasopharyngeal Carcinoma and EBV Infection, sponsored by Nanfang Hospital, Southern Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-12.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
The transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway. Therefore, we carried out this study to explore the changes of plasma and urine metabolites at different stages during the occurrence and development of nasopharyngeal carcinoma.
824 studies on the registry are indexed under Nasopharyngeal Carcinoma; 281 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 300 across 137 observational studies indexed under Nasopharyngeal Carcinoma.
Browse Nasopharyngeal Carcinoma studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 488 studies on the registry; 213 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects who met the diagnosis and criteria and were admitted to Nanfang Hospital of Southern Medical University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
QPCR/EBV antibody, diagnosed as EBV infection patient
Diagnostic Test: Proteomics technology and liquid biopsy
Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard)
Diagnostic Test: Proteomics technology and liquid biopsy
healthy people with no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism
Diagnostic Test: Proteomics technology and liquid biopsy
using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
Achieve the expected number of enrolled cases
Achieve the expected number of enrolled cases
Time frame: 3 years
Plan to share: No
This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University →